Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences
Shire $SHPG is getting in early on an investigational product that might one day replace IV infusions of concentrated antibodies given to patients to boost their immune systems. The move could get Shire’s foot in the door of a multibillion-dollar market.
These antibody cocktails, made from the plasma of thousands of blood donors, are often given to patients whose immune systems don’t make enough antibodies to fight germs that cause infections. The therapies, called intravenous immunoglobin or IVIg, are part of a market that’s projected to be worth $10.9 billion by 2022. But IVIg therapies are cumbersome to make and require visits to clinics or hospitals for patients to get treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
